First hospitalized COVID-19 patient treated with the antibody drug candidate COR-101

Braunschweig, April 22, 2021 – YUMAB spin-off CORAT Therapeutics announced the start of a clinical trial with COR-101 for treatment of COVID-19 in hospitalized patients. The novel therapeutic antibody may complement currently approved antibody drugs, which are not indicated for moderate to severe COVID-19 cases due to side effects during advanced stages of the disease.

Read CORAT’s press release (English)

Read CORAT’s press release (German)

Contact

YUMAB GmbH
Dr. Thomas Schirrmann, CEO
Phone: +49-531 481170-0
Email: info@yumab.com

CORAT Therapeutics GmbH
Dr. Andreas Herrmann, Managing Director
Phone: +49-152 2404 7488
Email: info@corat-therapeutics.com